[Skip to Content]
[Skip to Content Landing]
Controversies
July 2007

The Role of Topical Antibiotic Prophylaxis for Intravitreal Injections

Author Affiliations

Author Affiliations: Departments of Ophthalmology and Health Evaluation Sciences, Penn State College of Medicine, Hershey, Pennsylvania (Dr Scott); and Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida (Dr Flynn).

 

LEE M.JAMPOLMD

Arch Ophthalmol. 2007;125(7):974-976. doi:10.1001/archopht.125.7.974

Intravitreal injections have rapidly become a widespread technique to administer pharmacotherapies to treat a variety of posterior segment disorders, including exudative age-related macular degeneration,19 proliferative diabetic retinopathy,10 and macular edema associated with myriad conditions.1117 With the widespread use of the intravitreal injection technique, there has been increased concern regarding the risk of endophthalmitis following intravitreal injection. In recent multicenter clinical trials of anti–vascular endothelial growth factor therapy, the reported incidence of endophthalmitis has ranged from 1.0% to 1.9% per patient for 6 months to 2 years (depending on the study).1,2,5,18,19 Given this rate of endophthalmitis and the widespread use of the intravitreal injection technique, it is reasonable to consider the potential value of topical antibiotics as prophylaxis in an effort to minimize the risk of endophthalmitis associated with intravitreal injections.

First Page Preview View Large
First page PDF preview
First page PDF preview
×